FDA bats back As­traZeneca's SGLT di­a­betes drug for Type 1 di­a­betes — block­ing a class on safe­ty fears

The FDA has just fired its lat­est sal­vo at the SGLT class of di­a­betes drugs, blow­ing up some com­mer­cial op­por­tu­ni­ty at As­traZeneca as part of the col­lat­er­al dam­age.

The phar­ma gi­ant re­port­ed ear­ly Mon­day that the FDA has re­ject­ed its block­buster drug Farx­i­ga for Type 1 di­a­betes that can’t be con­trolled by in­sulin. And while the phar­ma gi­ant main­tained its usu­al grim si­lence in the face of a set­back, this one should be easy to in­ter­pret.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.